Supert👍

Nice ,går veien med hovedcaset ,go helg

Ingen fiasko på ASCO !

BERGENBIO PRESENTS DATA FROM PHASE I/II BEMCENTINIB/ERLOTINIB COMBINATION TRIAL IN NSCLC AT ASCO MEETING

Bergen, Norway, 04 June 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today presents end-of-trial data from a Phase I/II study of bemcentinib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Study Design

Phase I of the study was a dose escalation arm designed to confirm the safety and tolerability of bemcentinib in NSCLC patients as both monotherapy and in combination with erlotinib in patients whose disease had previously progressed on erlotinib alone.

Phase II assessed patients in two groups; those whose disease had progressed on an approved EGFR inhibitor, and those who were responding/stable on erlotinib as a first line treatment. Both groups were treated with bemcentinib and erlotinib to evaluate the safety and activity of the combination, while assessing reversal or prevention of resistance to EGFR inhibition.

Conclusions

Data from the study found that Bemcentinib in combination with erlotinib was well tolerated over extended periods of time, with the longest ongoing patients having been dosed for over 46 months.

The combination led to disease stabilisation and durable tumour responses in a proportion of patients who had previously progressed on EGFR targeted therapy and who were negative for the T790M resistance mutation. In patients who were responding to first line treatment with erlotinib, either stable disease or partial response, the addition of bemcentinib led to further deepening of responses and prolonged the duration of responses beyond 30 months in 4 out of the 13 patients evaluated. At the time of data cut-off, 2 patients are still participating in the study beyond 34 months of treatment. Ongoing patients at the time of study closure, who wish to continue receiving study treatment, will be offered the drug via an expanded access program.

Selvfølgelig fikk jeg ikke til å logge meg på. Prøvde å opprette konto men det ble bare tull. Regner ed at jeg får "referat fra møte her" dvs. diskusjoner ang. hvor bra eller dårlige nyheter.

Covid studiet fikk p>0,06 for ventilator free survival (VFS) i den dårligste pasient gruppen.
Ventilator Free Survival
• Defined as the proportion of patients that survived to day 29 day without admission to ICU and the need for ventilator assisted breathing
• A sub-group of patients treated with bemcentinib appeared to be protected from an early deterioration

Lurer på hva p hadde blitt om de hadde brukt denne definisjonen (legg merke til sucessful extubation)?

Ventilator-free days (VFD) is defined as being free from invasive mechanical ventilation for at least 48h (successful extubation). If the patient is re-intubated within 48 hours of the extubation it will be treated as zero VFD; if re-intubated after 48 hours, the 48 hours period will be counted as VFD. Patients discharged from the hospital alive before 28 days are considered alive and free from mechanical ventilation at day 28. Non-survivors at day 28 are considered to have zero VFD.

http://rbti.org.br/imagebank/pdf/RBTI-0226-20-en-para-site-16.07.pdf

Sitter du fast i heisen?

Hva er dette? Kan du være snill å forklare hva du mener her.

Hva Skjer’a.... trangt i heisen ? 🤣💦👍👏👏👏

Dette blir en flott slutt på uka og en end bedre start på mandag...

Gleder meg...

(«Hva Var Det Jeg Sa».... )

The COVID-19 pandemic has been met by unequal responses in different countries1, 2 and led to unequal impacts, with populations in Europe, the USA, and Latin America disproportionately impacted.3 Science has uncovered much about SARS-CoV-2 and made extraordinary and unprecedented progress on the development of COVID-19 vaccines, but there is still great uncertainty as the pandemic continues to evolve. COVID-19 vaccines are being rolled out in many countries, but this does not mean the crisis is close to being resolved. We are simply moving to a new phase of the pandemic.
What emerges next will partly depend on the ongoing evolution of SARS-CoV-2, on the behaviour of citizens, on governments' decisions about how to respond to the pandemic, on progress in vaccine development and treatments and also in a broader range of disciplines in the sciences and humanities that focus both on bringing this pandemic to an end and learning how to reduce the impacts of future zoonoses, and on the extent to which the international community can stand together in its efforts to control COVID-19. Vaccines alone, unless they achieve high population coverage, offer long-lasting protection, and are effective in preventing both SARS-CoV-2 transmission and COVID-19, will not end the pandemic or allow the world to return to “business as usual”. Until high levels of global vaccine-mediated protection are achieved across the world, it could be catastrophic if measures such as mask wearing, physical distancing, and hand hygiene are relaxed prematurely.4 Countries, communities, and individuals must be prepared to cope in the longer-term with both the demands and the consequences of living with such essential containment and prevention measures.
• View related content for this article
Many factors will determine the overall outcome of the pandemic. A nationalistic rather than global approach to vaccine delivery is not only morally wrong but will also delay any return to a level of “normality” (including relaxed border controls) because no country can be safe until all countries are safe. SARS-CoV-2 could continue to mutate in ways that both accelerate virus transmission and reduce vaccine effectiveness.5, 6, 7 Vaccine hesitancy, misinformation, and disinformation could compromise the global COVID-19 response.8 Naive assumptions about herd immunity, given the appearance of new and challenging SARS-CoV-2 variants,5, 9 could seriously risk repeated outbreaks and recurrences. SARS-CoV-2 can probably never be globally eradicated, because of its presence in many animals (including cats and dogs)10 and because of incomplete vaccine coverage and variable degrees of immunological protection.11 Hence, ongoing strategies to deal with the endemic presence of SARS-CoV-2 in populations over the long term will be needed. Furthermore, we do not yet know if, and when, revaccination with current or new COVID-19 vaccines will be required since the duration of immunological protection and the efficacy against emergent SARS-CoV-2 variants remain unknown. With such uncertainties, we should not assume that recent scientific progress on COVID-19 diagnostics, vaccines, and treatments will end the pandemic. The world is likely to have many more years of COVID-19 decision making ahead—there is no quick solution available at present.
The decisions of global agencies and governments, as well as the behaviours of citizens in every society, will greatly affect the journey ahead. There are many possible outcomes. At one extreme is the most optimistic scenario, in which new-generation COVID-19 vaccines are effective against all SARS-CoV-2 variants (including those that may yet emerge) and viral control is pursued effectively in every country in a coordinated effort to achieve global control. Even with international cooperation and adequate funding, this scenario would inevitably take a long time to achieve. The COVAX initiative is just an initial step towards addressing vaccine equity and global coordination for vaccine access, especially for lower income countries.12 At the other extreme is a pessimistic scenario, in which SARS-CoV-2 variants emerge repeatedly with the ability to escape vaccine immunity, so that only high-income countries can respond by rapidly manufacturing adapted vaccines for multiple rounds of population reimmunisation in pursuit of national control while the rest of the world struggles with repeated waves and vaccines that are not sufficiently effective against newly circulating viral variants. In such a scenario, even in high-income countries, there would probably be repeated outbreaks and the path to “normality” in society and business would be much longer. And there are many other intermediate or alternate scenarios.
Countries that have kept SARS-CoV-2 in check and countries where there are high levels of viral transmission will in time all probably reach a similar destination, even though their paths to arrive there will be quite different, because no countries can remain permanently isolated from the rest of the world. Unfortunately, countries working in isolation from each other and from global agencies will prolong the pandemic. A nationalistic rather than a global approach to COVID-19 vaccine availability, distribution, and delivery will make a pessimistic outcome much more likely. Additionally, unless countries work together to scale up prevention efforts, the risk of other pandemics, or other transboundary disasters with similar consequences, including those fuelled by climate change, will remain a constant threat.
The International Science Council (ISC), as the independent, global voice for science in the broadest sense, believes it is crucial that the range of COVID-19 scenarios over the mid-term and long-term is explored to assist our understanding of the options that will make better outcomes more likely. Decisions to be made in the coming months need to be informed not only by short-term priorities, but also by awareness of how those decisions are likely to affect the ultimate destination. Providing such analyses to policy makers and citizens should assist informed decision making.
In developing its COVID-19 Scenarios Project, the ISC has consulted with WHO and the UN Office for Disaster Risk Reduction. The ISC has established in February, 2021, a multidisciplinary Oversight Panel made up of globally representative world experts in relevant disciplines to work with a technical team to produce the scenario map. The Oversight Panel will report within 6–8 months to the global community on the possible COVID-19 scenarios that lie ahead over the next 3–5 years, and on the choices that could be made by governments, agencies, and citizens to provide a pathway to an optimistic outcome for the world.

The authors are members of the Interim COVID-19 Working Group of the ISC. DS is convener of the interim working group. PG is President-Elect of the ISC. GB is a member of the ISC Governing Board. HH is Chief Executive Officer of the ISC. SSAK is Co-chair of the South African Ministerial Advisory Committee on COVID-19. PP has received grants from the Bill & Melinda Gates Foundation and personal fees as special adviser from the European Commission and as Chair of the Board from the HMG SCOR Board, unrelated to the current project. CW is a member of the working group on pandemics and crisis of the Group of Chief Science Advisors to the European Commission and the European Group on Ethics in Science and New Technologies and has received grants from the German Federal Ministry of Research and Education, the German Federal Ministry for Family and Seniors, the Bertelsmann Foundation, the German Federal Ministry for Health, the German Federal Ministry of Justice and for Consumer Protection, personal fees from Agaplesion gAG as a member of supervisory board, and personal fees from several companies and organisations all unrelated to this Comment. We thank Felicia Low for her help in preparing this Comment.
References

1.Brauner JM Mindermann S Sharma M et al.
Inferring the effectiveness of government interventions against COVID-19.
Science. 2020; (published online Dec 15.)
https://doi.org/10.1126/science.abd9338
View in Article
Scopus (28)
PubMed
Crossref
Google Scholar
2.Allen K Buklijas T Chen A et al.
Tracking global evidence-to-policy pathways in the coronavirus crisis: a preliminary report.
International Network for Government Science Advice, Auckland2020
https://www.ingsa.org/wp-content/uploads/2020/09/INGSA-Evidence-to-Policy-Tracker_Report-1_FINAL_17Sept.pdf
Date accessed: February 15, 2021
View in Article
Google Scholar
3.Roser M Ritchie H Ortiz-Ospina E Hasell J
Coronavirus pandemic (COVID-19).
https://ourworldindata.org/coronavirus
Date: 2020
Date accessed: February 14, 2021
View in Article
Google Scholar
4.Haug N Geyrhofer L Londei A et al.
Ranking the effectiveness of worldwide COVID-19 government interventions.
Nat Human Behav. 2020; 4: 1303-1312
View in Article
Scopus (61)
PubMed
Crossref
Google Scholar
5.Fontanet A Autran B Lina B Kieny MP Abdool Karim SS Sridhar D
SARS-CoV-2 variants and ending the COVID-19 pandemic.
Lancet. 2021; (published online Feb 11.)
https://doi.org/10.1016/S0140-6736(21)00370-6
View in Article
Scopus (22)
PubMed
Summary
Full Text
Full Text PDF
Google Scholar
6.Chand M Hopkins S Dabrera G et al.
Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01.
Public Health England, London2020
View in Article
Google Scholar
7.Tegally H Wilkinson E Giovanetti M et al.
Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa.
MedRxiv. 2020; (published online Dec 22.) (preprint)
https://doi.org/10.1101/2020.12.21.20248640
View in Article
Google Scholar

Nå er det uansett så mye negativt rundt BergenBio at om det kommer en negativ melding til så vil ikke kursen kollapse, får håpe på noe positivt men det er vel å drømme :-)

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00424-4/fulltext

Takker

Takker.

09:00 AM EDT = 15:00 Oslo

Den kommer Kl 15:00 Oslo tid i ettermiddag (09:00 EDT / 13:00 GMT )

Dette er også et godt tidspunkt for å presentere en større nyhet om samarbeid og rettet emisjon på xxx Mill USD....

https://www.bergenbio.com/bergenbio-to-present-at-the-american-society-of-clinical-oncology-asco-annual-meeting/

Hva slags presentasjon dere snakker om? Jeg har sett på BergebBio sin side men ser ikke noe om presentasjon i dag? Hva er det, går det an å følge med, når på dagen skal det skje?

Ledelsen bør på banen når analytikere og portefølje forvaltere snakker om emisjon. Det er ingen vei utenom.

Det er gitt signaler om at det er kort tid igjen til at større ting er på gang. Jeg må beskytte mine kilder, men de er meget troverdige.

Hvis det ikke kommer avtaler eller at forhandlingene har strandet så blir det ørken vandring. Da kan jeg like gjerne vente til neste BerGenBingo dukker opp.

Forrige uke snakket du om avtaler var nært forestående, denne uken er det salg og slakting, hva har egentlig skjedd i mellomtiden?

Uvisst - Vi får se om det blir bunnfiske eller sløying ...

Mine opplysninger tyder på bunnfiske er best ....

Den skjulte Short posisjonene i BGBIO tror jeg nærmer seg 10% av utestående aksjer i selskapet.

Den blir nok avslørt snart...

Ingen oppdatering BIOBULL? Er det til mandag aksjene selges?

Blir naturligvis riktig så spennende å få rede på de svært så reflekterte utlegninger som meget snart bres ut av Bio og Longo

Kan du ikke legge dette på covid-tickeren? Madsen er for øvrig spesialist i hjertesykdommer. Mener du at dette øker sjansen for BEM som covid-medisin?
https://www.tv2.no/a/14022672/

Har dere noen forventninger om morgendagens presentasjon.? Skulle jo tro det vil ha en positiv effekt på aksjens verdi.eller.?

Takk for den rett etter eg har tatt den. Et ikke rart det er mange psykisk syke . Alt man gjør kan jo føre til døden..nå er jeg nærmere 40 enn 30. vi får håpe det går bra..

-This issue of a transient myocarditis associated with a vaccine is at the moment a theoretical and unproven risk," Offit said. "So I think that in the world of trying to weigh relative risks, the disease is a greater risk."

Litt om om Ptdser og covid-19.
Ifølge BergenBio:
-Enveloped viruses display PtdSer (phosphatidylserine) that binds to GAS6 & AXL.
-AXL & ACE2 required for endosomal viral entry to host cell»

Her en referanse og teori på at Phosphatidylserine (Ptdser) faktisk er på overflaten til covid viruset. At Ptdser tas fra (engelsk: bud) cellenes innside idet viruset replikeres eller rett etter:
https://www.sciencedirect.com/science/article/pii/S2405844021001389

«Figure 1. Phosphatidylserine exposure on the outside of cells and microparticles – Phosphatidylserine (PS) is maintained on the inner surface of the plasma membrane of all cells. Several mechanisms can lead to the “exposure” of PS on the external surface of cells. Physiologic or pathologic “activation” of cells can lead to exposure of phosphatidylserine (PS) on the external surface of cells, or microparticles released by cells.
Enveloped viruses bud from host cells, resulting in PS-bearing virions released into the intra- and extra-vascular spaces, depending upon the location of the infected cell.»

Artkkelen over, og artikkelen og video under gir mye forklaring på alvorlig covid-19 sykdomsforløp begrunnet med Ptdser.

https://www.youtube.com/watch?v=WJHUDGbKYd4

https://www.researchgate.net/publication/347935402_Phosphatidylserine_inside_out_a_possible_underlying_mechanism_in_the_inflammation_and_coagulation_abnormalities_of_COVID-19

https://www.express.co.uk/life-style/health/1444812/covid-new-strain-coronavirus-hybrid-indian-kent-variant-very-dangerous

"
The new hybrid reportedly has a Y144 deletion mutation in the spike protein.

This mutation "makes it harder for antibodies to stick to the coronavirus", said the New York Times."

Takk for påminnelsen 👌

By the way
https://www.bergenbio.com/careers/
https://www.bergenbio.com/jobs/associate-director-of-clinical-operations/

«Based within the Clinical Operations team you will be responsible for the execution of clinical development of the company’s assets in assigned portfolio. Your role will be to deliver clinical proof of concept and create a package ready for licensing or to move into phase Ill.»

Vkvamba
Det var synd for du kunne jo gjort tråden mer meningsfull. Folk som leser de fjollete hausse innleggene til BB må jo miste all interesse for aksjen.

Syns du begrunner din avkopling fra forum meget godt Vkvamba. All mulig lykke til med dine fremtidige disposisjoner og skriverier blant sparringpartnere som du mener holder mål!

Var ikke mye forfriskende å melde seg inn her. Prøvde meg på en objektiv korreks av påstanden om effekten av bemcentinib på corona, men da gikk et par (trolig dybt investerte småsparere som blør penger) i skyttergraven. Merket jeg ble usakelig i mine tilsvar etter å ha blitt provosert nok, så jeg melder meg ut. Med de aktørene som er i sving vedrørende manipulasjon av aksjen er det jo tragikomisk at de tror aksjekursen påvirkes basert på skriverier i et forum for småsparere. Det mener jeg er en kraftig nedvurdering av evnen folk har til å gjøre research før investering. Du skal være passe dum for å kjøpe aksjer basert på forum-haussing og rakett-emojis. Bergenbio har ikke levert som forventet i markedet, og da er aksjekursen en direkte konsekvens. Det spiller fuck all hva som skrives på et forum. Dette er ikke gamestop eller AMC der hypen nådde millioner av småsparere.

Jeg tror den nye samarbeids partneren til BerGenBio presser aksjekursen ned så langt som mulig før en rettet emisjon. Short posisjonen som nå er bygget opp i det skjulte begynner å bli rimelig stor. Om emisjonen kommer på 37 NOK , 47 NOK eller høyere er uvisst. Uansett vil det bli en billig inngangs verdi for den eller de som får trykket aksjer på billigsalg. Nyheten om samarbeidspartner(e) tror jeg er nært forestående - det samme gjelder emisjonen som ingen ordinære aksjonærer får ta del i.
Dette ble kritisert på GF - det samme ble opsjons-programmet så lenge aksje kursen avviker så dramatisk fra analytikernes forventninger.

Nå har ledelsen spilt sine kort så dårlig at det bør bli et saftig oppvask møte på styrerommet..

Jeg håper at hoved-aksjonærene tar ansvar og gjør det som trengs for gjenoppbyggingen av tillit.

Husk at penger er tillit - ikke BINGO !

På mandag kan aksjekursen i BerGenBingo være over 50kr.... vent & se ...

Jeg er nok fattig på penger men ser lys her utenfor fjøset

I de blindes rike er den enøyde konge

Det mest interessante er å se på NVP exibit 16 for de ulike kreft typene AML og NSCLC er basert på fase ii Probability of Success på 35%, mens en allerede nå har kliniske studier som i følge BergenBio indikerer (informs) at en skal over i fase iii. Og da tror jeg analytikere generelt bruker standard Probability of Success på 70% i studier hvor en kan bruke prediktive biomarkører, som i tilfelle BergenBio kalles CDX , basert på composit AXL (cAXL).

Se detaljer i exhibit 16, fra den meget grundige analysen nov 2019

https://www.edisongroup.com/publication/bemcentinib-leading-the-axl-charge/28247/

Det kaller jeg helt normal tilbakemelding til en CEO i Biotech som forsøker å manipulere markedet for så å hente personlig gevinst av det. Rett og slett det groveste jeg har sett. Aksjemarkedet reagerer som forventet. Dette skjønner de aller fleste.

Takk , Kursiv! En velsignelse å få noe som relaterer seg til aksjen. Trodde de svært negativt innstilte kranglende var i ferd med å få overtaket og råde grunnen alene her!

focuss
Du som er så opptatt av sjikanering - hva kaller du dette :

focuss
11.12.2020 kl 22:23
..........Godfrey fikk et kraftig tupp i ræva.

focuss
28.12.2020 kl 18:54
Godfrey gjør meg flau over og være norsk.I biotech trengs folk som kan skape tillitt. Ikke løgnere men mangelfull IQ.

focuss
28.12.2020 kl 21:03
For meg er Godfrey rett og slett for dum til at jeg sette mye penger på ham.

Godt at noen oppegåande analytikere har evnen til å se det store bildet i pandemien og vurderer ulike nå og framtidige behandlinger. Trekker ut essensen

see ‘Bemcentinib leading the AXL charge‘), COVID-19 could expediate its route to market in 2022. Its potential dual mechanism of action and convenient once-a-day oral dosing is initially being assessed in a hospitalised setting. Clinical development work to assess its potential use in a community setting or as a post-exposure prophylactic may be appropriate depending on the future status of the pandemic. We maintain our peak sales of $300m and adopt a ‘wait-and-see’ approach 

https://www.edisongroup.com/publication/bemcentinib-preliminary-data-in-covid-19/29329/

COVID-19 could expediate route to market
While bemcentinib is primarily being developed for oncology indications (see ‘Bemcentinib leading the AXL charge‘), COVID-19 could expediate its route to market in 2022. Its potential dual mechanism of action and convenient once-a-day oral dosing is initially being assessed in a hospitalised setting. Clinical development work to assess its potential use in a community setting or as a post-exposure prophylactic may be appropriate depending on the future status of the pandemic. We maintain our peak sales of $300m and adopt a ‘wait-and-see’ approach in light of global vaccination programmes and the progress of other potential treatments.

Valuation: NOK4.72bn or NOK53.8 per share
We continue to value BerGenBio at NOK4.72bn or NOK 53.8/share. Our forecasts remain unchanged. The key value drivers are bemcentinib in second-line NSCLC (peak sales $1.2bn, NOK37.2/share) and AML (peak sales $598m, NOK12.2/share) plus the COVID-19 opportunity (peak sales $300m, NOK5.4/share).

Move Along
Du skal vite at for meg fremstår det du skriver som dårlig analyse. Faktum er at dersom man skriver noe negativt om Godfrey eller BGBIO blir man sjikanert på det groveste. Det er ikke uvanlig at folk som blir møtt av en slik mobb tar igjen og blir forbannet. Når mobben samtidig legger frem vurderinger av en aksje som mangler alt av troverdighet grunnet dårlig kunnskap om både biotech og aksjemarkedet så blir det ikke bedre.

Det siste eksemplet har jo nå alle sett. En ny skribent med peiling kommer inn på forumet med gode innlegg. Hva skjer: Blir møt med anklager fornærmelser, blokkeringer etc. Det er BGBIO haussernes modus operandi.

Flott innlegg, belyser godt prosessen til amatørene, savner bare at de bruker flere brukernavn 👈

Vigdis88
Ingen trodde det var drivverdig olje der de fant Johan Sverdrup feltet bortsett fra en svært sta letesjef i Lundin. Den sta letesjefen i Lundin er ikke meg, men det han har bidratt med til statskassa går nok mange ganger utenpå Thon og Mohn til sammen..

Tror ikke du er en av de profesjonelle traderene Move Along sikter til. Jeg ser du er aktiv i de vanlige folkeaksjene som Rec, Koa osv. Du er nok en amatør som resten av oss 99%. Focuss derimot.. Jeg har regnet litt. For å ha bidratt med titalls milliarder til statskassen må man ha vært veldig rik i veldig mange år. Det kan være Olav Thon, muligens Trond Mohn, eller en av dem på Kapitals topp ti rikeste i Norge.

Føler meg rent beæret over å høre til den beskjedne skare utenfor fjøset som du stadig vier tanker til